Evidence map›Paper›PMID 38261961›Full record

Article3 Biotech2024

Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology.

Alda Corrado, Romina Aceto, Simona Miglietta, Roberto Silvestri, Irene Dell'Anno, Irene Lepori, Benedetta Ricci, Cristina Romei, Roberto Giovannoni, Laura Poliseno and 6 more

Abstract read
In one paragraph

Article in 3 Biotech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alda Corrado *Department of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Romina Aceto *Department of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Simona MigliettaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.
Roberto SilvestriDepartment of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Irene Dell'AnnoDepartment of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Irene LeporiInstitute of Clinical Physiology (IFC), CNR, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.
Benedetta RicciFondazione I.R.C.C.S., Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy.
Cristina RomeiEndocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Roberto GiovannoniDepartment of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Laura PolisenoInstitute of Clinical Physiology (IFC), CNR, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.
Monica EvangelistaInstitute of Clinical Physiology (IFC), CNR, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.
Marianna VitielloInstitute of Clinical Physiology (IFC), CNR, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.
Monica CipolliniDepartment of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
Rossella EliseiEndocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Stefano Landi *Department of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.ORCID 0000-0001-8364-6357
Federica Gemignani *Department of Biology, Genetic Unit, University of Pisa, Via Derna 1, 56126 Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of CRISPR/Cas9 system has rapidly grown in the last years. Here, the optimization of gene editing of a single-nucleotide polymorphism in a human non-malignant somatic cell line of thyrocytes (Nthy-Ori) was described highlighting strategies for overcoming the problems concerning the delivery and off-targets. We employed both lentivirus and chemical lipids as delivery agents and two strategies for creating the double-strand breaks (DSB). The former induced a DSB by a classical Cas9 nuclease (standard strategy), while the second one employed a modified Cas9 creating a single-strand break (SSB). The knock-in was carried out using a single-stranded donor oligonucleotide or the HR410-PA donor vector (HR). The desired cells could be obtained by combining the double nickase system with the HR vector transfected chemically. This result could be due to the type of DSB, likely processed mainly by non-homologous end joining when blunt (standard strategy) and by HR when overhanging (double nickase). Our results showed that the double nickase is suitable for knocking-in the immortalized Nthy-Ori cell line, while the standard CRISPR/Cas9 system is suitable for gene knock-out creating in/del mutations. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-023-03878-4.

Indexed as

CRISPR/Cas9Double nickase strategyHuman cell linesKnock-inSingle base DNA editing

Identifiers

PMID38261961
PMCPMC10798938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.